BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 855 filers reported holding BAXTER INTL INC in Q3 2013. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $290,000 | -2.7% | 3,600 | -2.7% | 0.08% | -2.5% |
| Q2 2021 | $298,000 | -6.9% | 3,700 | -2.6% | 0.08% | -14.1% |
| Q1 2021 | $320,000 | -0.3% | 3,800 | -5.0% | 0.09% | -3.2% |
| Q4 2020 | $321,000 | -0.3% | 4,000 | 0.0% | 0.10% | -6.9% |
| Q3 2020 | $322,000 | -6.4% | 4,000 | 0.0% | 0.10% | -11.3% |
| Q2 2020 | $344,000 | +0.9% | 4,000 | -4.8% | 0.12% | -14.8% |
| Q1 2020 | $341,000 | -7.6% | 4,200 | -4.8% | 0.14% | +12.5% |
| Q4 2019 | $369,000 | -4.4% | 4,413 | 0.0% | 0.12% | -9.8% |
| Q3 2019 | $386,000 | +6.9% | 4,413 | 0.0% | 0.13% | +5.6% |
| Q2 2019 | $361,000 | -1.6% | 4,413 | -2.2% | 0.13% | -3.8% |
| Q1 2019 | $367,000 | +20.3% | 4,513 | -2.7% | 0.13% | +2.3% |
| Q4 2018 | $305,000 | -14.8% | 4,638 | 0.0% | 0.13% | +5.8% |
| Q3 2018 | $358,000 | -10.9% | 4,638 | -14.7% | 0.12% | -17.7% |
| Q2 2018 | $402,000 | +13.6% | 5,438 | 0.0% | 0.15% | +10.5% |
| Q1 2018 | $354,000 | +0.6% | 5,438 | 0.0% | 0.13% | +3.9% |
| Q4 2017 | $352,000 | +3.2% | 5,438 | 0.0% | 0.13% | +4.1% |
| Q3 2017 | $341,000 | +2.7% | 5,438 | -0.9% | 0.12% | 0.0% |
| Q2 2017 | $332,000 | +16.5% | 5,488 | 0.0% | 0.12% | +6.0% |
| Q1 2017 | $285,000 | +14.9% | 5,488 | -1.8% | 0.12% | +8.4% |
| Q4 2016 | $248,000 | -6.8% | 5,588 | 0.0% | 0.11% | -5.3% |
| Q3 2016 | $266,000 | +1.5% | 5,588 | -3.5% | 0.11% | +2.7% |
| Q2 2016 | $262,000 | +6.5% | 5,788 | -3.3% | 0.11% | +2.8% |
| Q1 2016 | $246,000 | +14.4% | 5,988 | +6.2% | 0.11% | +11.5% |
| Q4 2015 | $215,000 | +20.1% | 5,638 | +3.7% | 0.10% | +15.7% |
| Q3 2015 | $179,000 | -52.9% | 5,438 | 0.0% | 0.08% | -48.8% |
| Q2 2015 | $380,000 | +1.9% | 5,438 | 0.0% | 0.16% | +4.5% |
| Q1 2015 | $373,000 | -6.5% | 5,438 | 0.0% | 0.16% | -8.3% |
| Q4 2014 | $399,000 | +1.3% | 5,438 | -0.9% | 0.17% | -3.4% |
| Q3 2014 | $394,000 | 0.0% | 5,486 | +0.9% | 0.18% | -2.8% |
| Q2 2014 | $394,000 | -1.5% | 5,438 | 0.0% | 0.18% | -8.6% |
| Q1 2014 | $400,000 | +5.8% | 5,438 | 0.0% | 0.20% | +4.8% |
| Q4 2013 | $378,000 | +5.9% | 5,438 | 0.0% | 0.19% | -5.5% |
| Q3 2013 | $357,000 | -5.3% | 5,438 | 0.0% | 0.20% | -11.6% |
| Q2 2013 | $377,000 | -4.6% | 5,438 | 0.0% | 0.22% | -3.8% |
| Q1 2013 | $395,000 | +9.1% | 5,438 | 0.0% | 0.23% | -8.9% |
| Q4 2012 | $362,000 | – | 5,438 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |